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Current evidence from monogenic Parkinson's disease (PD) supports the view that PD is a clinical syndrome, 
rather than a single disease entity, and that the heterogeneity of PD indeed reflects different pathogenesis. Recent 
developments in functional imaging have enabled the in vivo assessment of cellular and molecular pathology of PD 
with respect to temporal and topographical patterns. We propose that this new technology will be useful for linking 
monogenic and sporadic PD, and thus, for classifying PD based on the pathogenesis. It will be also useful in 
clinico-genetic studies exploring susceptibility factors and at-risk groups, which are important for neuroprotective 
treatment when it becomes available. 
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INTRODUCTION
Positron emission tomography (PET) and single-photon 
emission computed tomography (SPECT) visualize and 
estimate quantitatively metabolic, biochemical or func-
tional activities in a living brain; hence, called as funct-
ional imaging. Since SPECT and PET were first 
introduced in Korea in 1986 and 1994 respectively, 
technical advances and availability have grown at a 
remarkable pace. As of 2005, there are 187 SPECT 
cameras, 54 PET or PET/CT, 4 microPET, and 15 
cyclotrons (which produce radiolabeled tracers) across 
the country; moreover, SPECT/CT fusion and high- 
resolution research tomograph (HRRT) will be intro-
duced. In the future, it may be possible to see high- 
resolution Compton gamma camera and PET/MR fusion 
made in Korea. There is no doubt that the rapid 
expansion of this infrastructure will contribute enormously 
to efforts of neuroscience community searching for 
prevention or curative treatment of neurodegenerative 
disorders - the last frontier of medicine. 
The goal of this review is to discuss the current issues 
on Parkinson’s disease (PD), and establish the rationale 
for using this relatively new technology in clinical 
research and practice for PD.
DEFINITION OF PARKINSON’S DISEASE
In 1817 at the start of the Industrial Revolution, 
James Parkinson first reported PD in his monograph, Journal of Clinical Neurology: Vol. 2, No. 2, 2006
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Gene 
(Locus)
Time course Symptomatology Pathology Molecular pathogenesis
Parkin / Park2 
(6q); AR
YOPD in most with slow 
progression; 50% of 
familial 
YOPD; 10~20% of 
apparently sporadic YOPD.
Responsive to very low 
dose of L-dopa; 
dementia very rare; 
olfactory function 
preserved
Nigral cell loss ± tau; 
LB in compound 
heterozygotes.
8
E3 ligase; Involve 
mitochondria ?
Single heterozygous 
mutation may be a 
risk.
PINK1 / 
Park6 (1p); 
AR
YOPD with slow 
progression; the second 
common familial YOPD 
next to Park2
Similar to Park2 Not available Kinase in 
mitochondria. 
Oxidative stress?
5,25
DJ-1 / Park7 
(1p); AR
YOPD with slow 
progression; very rare
Similar to Park2 Not available Oxidative 
stress?
64,65
SNCA / Park1 
(4q); AD
Onset (>50 y), progression: 
indistinguishable from IPD 
Duplication: onset 38~65 y. 
Triplication: onset 24~48 y 
with more rapid 
progression. 
L-dopa responsive, ass 
with dementia, 
autonomic dysfunction; 
5-6% of familial and 
1-2% of apparent 
sporadic PD
Typical PD; 
widespread LB; DLBD 
with prominent nigral 
and hippocampal 
(CA2-3) neuronal loss.
Synaptic? 
Underlying disease 
process is 
α -synuclein 
accumulation with 
gene-dose effects 
11
LRRK2/ 
Park8 (12p); 
AD
Onset (50~70 y), 
progression: 
indistinguishable from IPD
Similar to sporadic 
late-onset PD; rarely 
dementia or amyotrophy
Pleomorphic; typical 
LB, DLBD, tauopathy, 
or nigral cell loss
6,7 
Abnormal 
MAPKKK 
signaling
22,23 
*UCHL1 and glucosidase mutations are not listed because of their rarity or limited distribution.
Table 1. Clinical and pathological features of monogenic PD
“An Essay on the Shaking Palsy” based on his obser-
vations as a physician in East London. In 1888, Jean- 
Martin Charcot, then prominent French neurologist, 
pointed out that patients with this disorder do not have 
real weakness nor always have tremor, and thus, shaking 
palsy or paralysis agitans is a misnomer. He renamed 
this disorder as Parkinson’s disease. In 1912, Friedrich 
Lewy, German neurologist in Alois Alzheimer’s labo-
ratory, first described Lewy bodies. In 1960, Hornykiewics 
showed that the dopamine content of the substantia nigra 
and corpus striatum in postmortem PD brains was 
extremely low, less than 10% of normal, ushering into 
an L-dopa era. In 1997, Polymeropoulos et al reported 
the first genetic cause of PD, mutations in the SNCA 
(α -synuclein) gene.
1 Two months later, Spillantini et al 
showed that α -synuclein was a major component of 
Lewy bodies in sporadic PD, linking genetic and sporadic 
PD.
2 It has opened the third era in PD.
The diagnosis of PD has been based on clinical and 
pathological features. UK PD Society Brain Bank clinical 
diagnostic criteria (one of most stringent criteria, widely 
used for research purposes; also known as QSBB 
criteria) consist of three steps: (1) diagnosis of parkin-
sonian syndrome; (2) exclusion of atypical features 
including significant family history and early severe 
dementia; (3) supportive prospective positive criteria 
observed during the longitudinal evaluation.
3 The clinical 
diagnosis of PD is confirmed by postmortem patho-
logical examinations with loss of pigmented neurons and 
the presence of Lewy bodies in the substantia nigra. 
Based on these criteria, 76% of clinically diagnosed PD 
was confirmed pathologically.
4 This traditional way of 
defining PD is challenged by mounting new information 
derived from studies in familial PD.Lee CS, et al. Syndromic Approach to Parkinson’s Disease 
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CHANGING CONCEPT: 
PD AS A CLINICAL SYNDROME
Since the first report of a familial PD with mutations 
in  α -synuclein gene in 1997, at least five more genes 
have been identified as a causative mutation in familial 
PD (Table 1).
5 Subsequent clinical and pathological studies 
of affected people in these families revealed unexpected 
findings. First, patients with leucine-rich repeat kinase 2 
(LRRK2) mutation showed pleomorphic pathology even 
within a family: Lewy bodies, tauopathy or neuronal loss 
without intracellular inclusions.
6,7 Patients with parkin 
mutations showed dopamine neuronal loss without intra-
cellular inclusions and/or tauopathy in most cases, and 
Lewy bodies in some with heterozygous mutation.
8 
Interestingly, previous pathological studies in clinically 
diagnosed sporadic PD also reported a few cases 
showing neuronal loss without intracellular inclusions
9 or 
tauopathy.
10 Second, clinical phenotypes and pathological 
features ranged from typical idiopathic PD to diffuse 
Lewy body disease between individuals with mutation in 
the same gene, encoding LRRK2
7 or α -synuclein multi-
plication.
11 Third, seemingly sporadic PD might in fact 
have a genetic basis, blurring the boundary between 
sporadic and familial PD.
12-14 Therefore, significant 
family history should not exclude the diagnosis of PD,
15 
as in the current QSBB criteria. These observations also 
indicate that the presence of Lewy bodies in the 
postmortem brain cannot be used to “confirm” the 
disease
16 because the pathology of PD is likely an 
outcome of disease process, i.e. phenotype, rather than a 
determining factor of the disease.
NEW APPROACH TO PD: A NEED 
FOR PATHOGENIC CLASSIFICATION
Traditional belief that PD is a relatively homogeneous 
disease entity, which can be separated from other similar 
disorders by applying stringent diagnostic criteria, has 
crumbled. Now, we have definite evidence for the long- 
standing argument that PD is a clinical syndrome.
17,18 
More than 100 years ago, Charcot changed the name of 
this disorder, “shaking palsy” that is a syndromic 
description, to “Parkinson’s disease” that implies a homo-
geneous entity as a disease. After all, this revised term 
is turned out to be a misnomer again.
What is the impact of these new developments in 
everyday practice? Perhaps, the most compelling issue is 
whether the diagnosis of PD will be good enough for the 
treatment of disorder. Will this syndromic diagnosis 
guide us to tell patients the prognosis and definite 
treatment? From the clinician’s viewpoint, it is most 
useful if a disease is defined and classified based on the 
pathogenesis. By analogy, the diagnosis of pneumonia is 
not sufficient for the treatment. The physician should 
understand the underlying pathogenic process, e.g. 
infection, autoimmune or aspiration. Then, is it possible 
to categorize idiopathic sporadic PD based on patho-
genesis?
The study of genetics has been successful in identi-
fying key proteins and causative mutations in familial 
PD. It will continue to make headway in elucidating 
molecular pathogenesis of familial PD. However, mono-
genic PD explains only 20% of the early onset PD and 
less than 3% of the late onset PD.
19 The rest are all 
sporadic and idiopathic PD. Can we then relate findings 
i n  f a m i l i a l  P D  t o  s p o r a d i c  P D ?
Clinical phenotypes of familial PD, if all subtypes are 
lumped together, are as heterogeneous as those of 
sporadic PD. However, it is relatively homogeneous in 
each subtype of familial PD. The clinical phenotypes of 
dominant parkinsonism, especially Park8, are largely 
indistinguishable from typical late-onset idiopathic PD. 
The phenotype of Park1 is an aggressive dopa- 
responsive parkinsonism with earlier onset (mean age of 
46.5 years) and more rapid progression, compared with 
typical idiopathic PD.
20 It also shows a gene-dose effect 
on clinical and pathological phenotypes, more extensive 
with greater multiplication of α -synuclein gene.
11 These 
findings clearly demonstrate that the mutated gene is a 
major, but not exclusive, factor determining clinical and 
pathological phenotypes. Mutations in α -synuclein gene 
are known to cause abnormal lipid and vesicle dynamics,
21 
while mutations in LRRK2 gene are to cause abnormal 
MAPKKK (mitogen-activated protein kinase kinase 
kinase) signaling.
22,23 Journal of Clinical Neurology: Vol. 2, No. 2, 2006
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Figure 1. In Parkinson’s disease (PD), pathological and clinical features are two major phenotypes, largely determined by pathogenic 
mechanisms. Pathological phenotype includes the molecular type (e.g. α -synuclein, or tauopathy) and topographical distribution. Clinical
phenotype includes the time course (e.g. age at onset, the rate of progression) and symptomatology (e.g. parkinsonism, dementia, or 
autonomic dysfunction). (1) Molecular pathology reflects underlying pathogenic mechanisms.
25 (2) Regional selectivity of pathology is 
derived from selective vulnerability of affected neurons to the pathogenic process.
66 (3) Temporal course of PD also reflects underlying
pathogenic mechanisms. For example, mutations in parkin, DJ-1 or PINK1 are associated with young-onset PD with slow progression.
Park1 shows a gene-dose effect, more aggressive with greater multiplication (see the text). (4) Symptomatology is determined by the 
location of pathology. For instance, nigral tauopathy  produces  parkinsonism, indistinguishable from Lewy  body PD.
10 
In contrast, the clinical phenotype of recessive parkin-
sonism (e.g. Park2, Park6 and Park7 with mutations in 
parkin, PTEN-induced putative kinase 1 (PINK1) and 
DJ-1 respectively) is typically a young-onset PD (YOPD, 
the onset between 20~40 years of age) with slow pro-
gression and good response to L-dopa. This triad of 
recessive genes is variably associated with mitochondria, 
and protective against mitochondrial dysfunction and 
oxidative stress.
24,25 Although the pathological data are 
not available to all subtypes, at least, Park2 shows neuronal 
loss generally without protein aggregation, distinct from 
mutations in dominant genes that produce protein aggre-
gation pathology.
25 Therefore, while different gene 
mutations are associated with different pathogenic mecha-
nisms and different clinical and pathological phenotypes, 
those with similar pathogenic mechanisms tend to show 
similar clinical phenotype (Fig. 1). 
If one accepts the argument that the pathogenic 
mechanism is a major factor determining clinical and 
pathological phenotypes, one may assume that the 
pathogenic mechanism of a subtype of sporadic PD 
would be similar to that of familial PD with similar 
clinical and pathological phenotypes. It has been thought 
that heterogeneity in sporadic idiopathic PD may suggest 
the existence of subgroups within the disorder, with 
distinct clinical patterns and perhaps different pathogenic 
mechanisms.
26 However, without a specific biologic 
marker or a test, the subtyping of sporadic PD has been 
entirely dependant on clinical features: specific motor 
symptoms (tremor predominant vs. postural instability 
and gait difficulty, PIGD), age at onset (young-onset vs. 
old-onset), accompanying dementia, or data-driven 
approach without a priori assumption.
27,28 Fifteen years 
ago, Graham et al reported interesting findings in their 
data-driven approach, which are relevant to the current 
observations in familial PD. They could identity 3 
distinctive subtypes in sporadic PD: the “motor only”, 
“motor and cognitive”, and “rapid progression”.
27 The 
“motor only” subtype could correspond to benign YOPD 
in most recessive parkinsonism, whereas the “motor and 
cognitive” and the “rapid progression” could correspond 
to Park8 and Park1 (with duplication or triplication) 
respectively. This example demonstrates that a parallelism 
may indeed exist between sporadic and familial PD with Lee CS, et al. Syndromic Approach to Parkinson’s Disease 
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Figure 2. Stepped approach to explore the pathogenesis of sporadic PD. The basic tenet underlying this approach is that subgroups of
familial and sporadic PD with similar clinical and pathological phenotypes are likely to share pathogenic mechanisms. (1) Define the 
spectrum of clinical phenotype, findings of pathological imaging, and genotype in familial monogenic PD. (2) Identify a cluster of sporadic
PD, whose clinical phenotype and pathological imaging findings are similar to those of a subtype of familial PD. (3) Epidemiological
and clinico-genetic studies are conducted in this relatively homogeneous subgroup of sporadic PD to identify genetic susceptibility factors
and  gene-environmental interactions.
respect to the disease phenotype. Recently, new applica-
tion of PET and SPECT for exploring biochemical and 
pathological aspects of disease,
29-31 which will be 
discussed in the following sections, makes it possible to 
test this hypothesis by providing necessary biomarkers 
for sporadic PD (Fig. 2). 
CURRENT STATE OF FUNCTIONAL 
IMAGING FOR FAMILIAL PD
In recent years, PET and SPECT have been 
increasingly used for studies on familial PD. In 2001, 
Hilker et al in Germany reported a [
18F]-dopa PET study 
in 5 symptomatic and 5 asymptomatic family members 
with parkin mutation.
32 No significant differences were 
found between familial and sporadic PD. Interestingly, 
asymptomatic carriers with heterozygous mutations 
showed mild but significant reduction of Ki (by about 
18%) without a rostrocaudal gradient. In the following 
year, UK Hammersmith group reported two serial 
observations over up to 10 years: 4 symptomatic parkin 
patients showed slower progression than sporadic PD, 
whereas 4 asymptomatic parkin carriers (2 had serial 
scans) showed mild reduction of Ki but without signifi-
cant progression.
33 In 2003, a French study reported no 
significant differences in [
18F]-dopa findings between 19 
parkin patients and 6 parkin-negative, sporadic YOPD.
34 
In 2005, the UK Hammersmith group confirmed their 
earlier observations in asymptomatic parkin heterozygotes, 
showing mild reduction of Ki without anteroposterior 
gradient in the striatum.
35 
[
18F]-dopa PET study for patients with PINK1 muta-
tions also showed significant reduction of [
18F]-dopa Ki 
in the striatum, more so in the putamen.
36 As in parkin 
mutations, asymptomatic carriers with heterozygous 
PINK1 mutation showed mild reduction of Ki without 
significant anteroposterier gradient. Recent findings of 
[
123I]-β -CIT SPECT in a patient with PINK1 homozygous 
mutation was similar to those of [
18F]-dopa PET.
37 Journal of Clinical Neurology: Vol. 2, No. 2, 2006
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Recent [
18F]-FP-CIT PET study in a Turkish family with 
DJ-1 mutations showed significant reduction of 
[
18F]-FP-CIT binding in the striatum with significant 
rostrocaudal gradient in a patient with homozygous 
mutation, but mild reduction only, without significant 
rostrocaudal gradient in asymptomatic sister with 
homozygous mutation.
38 
Mutations in the LRRK2 gene cause autosomal 
dominant parkinsonism that is clinically and pathol-
ogically indistinguishable from typical late-onset, sporadic 
idiopathic PD.
7,39 Moreover, the disease penetrance in 
LRRK2 carriers is age-dependent, increasing from 17% 
at age 50 years to 85% at age 70 years,
40 simulating the 
age-dependent increase of sporadic idiopathic PD. 
[
18F]-dopa PET in two patients with LRRK2 mutation 
did not show significant differences from idiopathic 
PD.
41 The collaborative study between people in Van-
couver and Mayo Jacksonville, using three presynaptic 
tracers of [
18F]-dopa, [
11C]-methylphenidate (MP, for DA 
transporter) and [
11C]-dihydrotetrabenazine (DTBZ, for 
VMAT2 in the synaptic vesicle of monoaminergic 
terminals), showed similar findings between 4 sympto-
matic patients with LRRK2 mutation and sporadic 
idiopathic PD. Two asymptomatic carriers showed mild 
reduction of [
11C]-DTBZ and [
11C]-MP binding, but not 
[
18F]-dopa Ki, suggestive of possible compensatory 
changes in the preclinical stage.
42 [
123I]-ioflupane SPECT 
study in 10 Italian patients with LRRK2 mutation (7 
familial, 3 sporadic) also did not show significant differ-
ences between PD with LRRK2 mutation and without 
mutation.
43 
FUTURE PROSPECTS: 
PATHOLOGICAL IMAGING
Functional imaging in familial PD has been conducted 
using only dopamine tracers. Heterogeneity of familial 
and sporadic PD is, however, largely accounted for by 
non-dopamine and Alzheimer pathology; thus, PET or 
SPECT with multiple tracers can explore the extent of 
chemical or morphological pathology in the brain. There 
are three potentially useful tracers, which are in line 
with our interests. 
The first tracer is a cholinergic ligand. Dementia is the 
most important variable in the categorization of PD, and 
attributed to multiple mechanisms including cortical 
cholinergic deficits,
44-46 Alzheimer pathology and cortical 
Lewy pathology in addition to dopamine or other mono-
amine deficits. 
11C-labeled acetylcholine analog is a 
presynaptic marker, measuring the activity of acetyl-
choline esterase in the cortex (which reflects cholinergic 
terminal density). There are two types: [
11C]- MP4A 
(methylpiperidin-4-yl acetate) developed in Japan, and 
[
11C]-PMP (methyl-piperidin-4-yl propionate) developed 
in Ann Arbor, USA. Both have similar biological 
characteristics. PET studies using one of these ligands 
have been reported for patients with Alzheimer disease 
(AD),
47-49 PD and PSP,
50 PD with dementia,
51 and 
subjects with MCI.
52 These ligands are affected by 
acetylcholine esterase inhibitors, such as donepezil, which 
can be a problem for patients on this drug.
53 However, 
[
123I]-IBVM (iodobenzovesamicol), SPECT tracer, binds 
to acetylcholine vesicular transporter;
54 thus, is not likely 
affected by acetylcholine esterase inhibitors. A SPECT 
study using this tracer in AD and PD patients was 
reported in 1996.
54 
The next tracer of interest is [
11C]-OH-BTA-1, com-
monly called as Pittsburgh Compound-B (PIB). This 
PET tracer is a derivative of thioflavin-T, which is 
amyloid-binding histological dye.
55 In 2004, Klunk et al 
in Pittsburgh reported marked [
11C]-PIB binding in the 
association cortex of AD patients, which inversely 
correlated with [
18F]-FDG (fluorodeoxyglucose) uptake.
29 
Postmortem pathological studies have reported that 
Alzheimer pathology is common in most, but not all,
56 
PD patients with dementia.
57,58 The natural history of 
Alzheimer pathology in relation to Lewy pathology is 
not known.
59 At present, [
11C]-PIB PET studies for PD 
with dementia and dementia with Lewy bodies are being 
conducted in some centers. SPECT tracer for amyloid 
plaque is currently under development.
The third tracer of interest is [
11C]-PK11195, a PET 
ligand originally developed for the peripheral benzodia-
zepine binding site (PBBS).
60 Since PBBS expresses in 
activated microglia, it began to be used for neuro-
degenerative disorders after McGeer reported abundant 
activated microglia in the PD and AD brains.
61,62 This Lee CS, et al. Syndromic Approach to Parkinson’s Disease 
- 89 -
tracer is potentially important because microglial response 
may be used as a marker for disease activity in PD, 
which is otherwise not available. Therefore, in principle, 
it may localize the area of brain where the disease 
process is active, and also may show the time course of 
disease activity in a given region - findings which would 
be highly meaningful for the study of putative neuro-
protective agents. In 2005, Ouchi et al first reported a 
study in PD patients, using two tracers of [
11C]-(R)- 
PK11195 and [
11C]-CFT (carbomethoxy-3 beta-(4-fluoro-
phenyl)tropane; DAT ligand).
30 They found increased 
binding of [
11C]-(R)-PK11195 in the PD patients, 
particularly in the midbrain, which correlated inversely 
with [
11C]-CFT binding in the putamen. In the following 
year, the UK Hammersmith group reported a longitu-
dinal [
11C]-(R)- PK11195 PET study in PD patients, 
which did not show significant changes over 2 years.
63
In summary, with a variety of tracers that can provide 
biochemical and molecular aspects of pathology, we are 
now in a position to explore longitudinal changes of 
pathology in PD patients. The “functional” imaging is 
evolving into the “pathological” imaging; thus, for the 
first time since James Parkinson’s clinical report, it 
becomes a reality to combine the two major expressions 
of disease, i.e. clinical and pathological phenotypes, in 
real time.
CONCLUSIONS
Throughout the history, advances in scientific techno-
logy have led to new discoveries and innovative treat-
ments in medicine. With a rapid development of 
computed imaging device and radiopharmaceuticals, we 
are now facing a new opportunity for PD, almost 200 
years after first reported. Functional imaging will make 
it possible to categorize PD into subtypes with distinct 
pathogenesis. It will be also instrumental for clinico- 
genetic studies identifying susceptibility factors and 
at-risk groups, which are essential for successful neuro-
protective treatment when it becomes available.
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